Autoimmune meningoencephalitis associated with anti-glutamic acid decarboxylase antibody following covid-19 infection: A case report Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy

Mehri Salari¹, Bahareh Zaker Harofteh¹, and Masoud Etemadifar²

¹Shahid Beheshti University of Medical Sciences ²Isfahan University of Medical Sciences

April 25, 2022

Abstract

Anti-glutamic acid decarboxylase(Anti-GAD) are associated with various neurologic condition; but, no meningitis has been reported with it, so far. Evidence demonstrates the associated of autoimmune meningoencephalitis with Covid-19 infection. Here we report a 44-year-old female with progressive loss of consciousness with anti-GAD65 meningoencephalitis after Covid-19 infection.

Introduction

Anti-glutamic acid decarboxylase(GAD) are associated with various neurologic conditions, including stiff person syndrome, cerebellar ataxia, and limbic/extra-limbic encephalitis, seizure, cognitive impairment and behavioral disturbance(1–3). Growing evidence reveals the association of autoimmune meningoencephalitis with Covid-19 infection(4). Here we report a patient with anti-GAD65 autoimmune meningoencephalitis, post Covid-19 infection.

Case presentation

A 44-year-old female known case chronic bronchitis who was admitted by respiratory distress one months ago, and received Remdesivir by diagnosis of COVID-19 infection, after 10 days she discharged with clinical improvement. Twenty days after disease onset, the patient gradually developed memory loss and confusion, therefore, she admitted again. On examination she was confused without any focal neurological deficits, she did not have fever and meningeal irritation. Her pupils were isochoric and reactive and plantar reflex were down going. Brain CT showed severe hydrocephalus (figure 1). Brain MRI did not show any other pathologies. Lumbar puncture was done and CSF analysis revealed high protein, low glucose and pleocytosis (Table 1) and treatment with ceftriaxone (2gr/BD) and vancomycin (1gr/BD) got started and we continued the treatment. Due to severe hydrocephalus brain extra ventricular drainage was done for her. The EEG showed generalized slow activity. CSF evaluated for fungal, tuberculosis, brucellosis, sarcoidosis, and viral infections including HSV-1,2 and CMV, and autoimmune antibodies, and they came back positive for anti-GAD65 (Table 1). Malignancy and vasculitis work-up were negative. Due to the negative CSF culture, antibiotics discontinue and was started 7-day course of 1g/day IV methylprednisolone and she responded very well to medication and became conscious again and oriented without hallucination and illusion. Unfortunately, patient had pulmonary thromboembolism(PTE) in hospitalization and she died.

Discussion

Neurological manifestations are reported in 6-36% of patients with Covid-19. They could be divided in to direct(viral), secondary and post (para) infections(autoimmune)(5). Studies carried out since the Covid-19 outbreak have revealed conflicting statistics on the incidence of meningoencephalitis in various countries(6). It may be speculated that cases of meningoencephalitis related to Covid-19 may not actually reflect direct viral invasion to CNS, post-/para-infection immune pathologies might come in to play in some of the clinical presentations(7). 28 articles reporting 48 patients with infectious or immune-mediated Covid-19 CNS-disease, 5 patients presented with meningoencephalitis and 11 cases with autoimmune encephalitis(8). Zamani et. al, 2021 conducted a systematic review of 26 case reports on Covid-19 related meningoencephalitis that all patients presented with altered mental status and mild/moderate pleocytosis or proteinorrhachia in CSF (4). Anti-GAD antibody is found in some neurological syndromes, including stiff-person syndrome (60-80%), Limbic encephalitis (17%), cerebellar ataxia (2%), epilepsy (2.1-5.4%) and Miller Fisher syndrome, eye movement disorders, palatal myoclonus and Parkinson's disease rarely occur(9–11). But, no cases have reported with anti-GAD65 meningitis, so far (Table 2). The interesting finding of our case is presentation of GAD-65 with meningoencephalitis after Covid-19 infection.

Funding

None

Acknowledgment

None

Conflicts of interest

The authors declare no conflict of interest.

Ethics statement

Written informed consent was obtained from sister of the patient to publish this report in accordance with the journal's patient consent policy.

Detailed author's contribution

All the authors have contributed equally to conception, design, manuscript preparation, critical revision, and finalization. All the authors agree to be accountable for all aspects of the work.

Data availability statement

The authors confirm that the data supporting the finding of this study are available within the article

1. Ren C, Ren H, Ren X, Zhang W, Li J, Dai L, et al. Case Report: Autoimmune Encephalitis Associated With Anti-glutamic Acid Decarboxylase Antibodies: A Pediatric Case Series. Front Neurol [Internet]. 2021 Apr 12 [cited 2022 Mar 26];12. Available from: https://pubmed.ncbi.nlm.nih.gov/33912125/

2. Ben Achour N, Ben Younes T, Rebai I, Ben Ahmed M, Kraoua I, Ben Youssef–Turki I. Severe dysautonomia as a main feature of anti-GAD encephalitis: Report of a paediatric case and literature review. Eur J Paediatr Neurol. 2018 May 1;22(3):548–51.

3. McKeon A, Tracy JA. The immunobiology of autoimmune encephalitides. Muscle and Nerve. 2017 Jul 1;56(1):15–27.

4. Zamani R, Pouremamali R, Rezaei N. Central neuroinflammation in Covid-19: a systematic review of 182 cases with encephalitis, acute disseminated encephalomyelitis, and necrotizing encephalopathies. Rev Neurosci [Internet]. 2021 Sep 17 [cited 2022 Mar 25]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/34536341 5. Kutlubaev MA. Clinical and pathogenetic aspects of nervous system impairments in covid-19. Zhurnal Nevrol i Psihiatr Im SS Korsakova. 2020;120(9):130–6.

 Moghimi M, Moghtader A, Jozpanahi M, Khodadadi K, Jafarzade M, Abbaspour Z. Correlation between CSF biomarkers and COVID-19 meningoencephalitis: A case series. Respir Med case reports [Internet].
2021 Jan 1 [cited 2022 Mar 25];32:101335. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33398243

7. Mondal R, Ganguly U, Deb S, Shome G, Pramanik S, Bandyopadhyay D, et al. Meningoencephalitis associated with COVID-19: a systematic review. Vol. 27, Journal of NeuroVirology. Springer Science and Business Media Deutschland GmbH; 2021. p. 12–25.

8. Finsterer J, Scorza FA. Infectious and immune-mediated central nervous system disease in 48 COVID-19 patients. J Clin Neurosci. 2021 Aug 1;90:140–3.

9. Bhandari HS. Rare disease: Presentation of opsoclonus myoclonus ataxia syndrome with glutamic acid decarboxylase antibodies. BMJ Case Rep [Internet]. 2012 [cited 2022 Apr 4];2012. Available from: /pmc/articles/PMC4543362/

10. Tohid H. Anti-glutamic acid decarboxylase antibody positive neurological syndromes. Neurosciences [Internet]. 2016 [cited 2022 Apr 4];21(3):215. Available from: /pmc/articles/PMC5107286/

11. Dade M, Berzero G, Izquierdo C, Giry M, Benazra M, Delattre JY, et al. Neurological syndromes associated with anti-gad antibodies. Int J Mol Sci. 2020 May 2;21(10).

12. Dogan L, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO, et al. Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series. Brain Behav Immun. 2020 Jul 1;87:155–8.

13. Ballout AA, Babaie A, Kolesnik M, Li JY, Hameed N, Waldman G, et al. A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines. Front Neurol [Internet]. 2022 Feb 24 [cited 2022 Mar 25];13:796882. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35280277

14. Lv P, Peng F, Zhang Y, Zhang L, Li N, Sun L, et al. COVID-19-associated meningoencephalitis: A care report and literature review. Exp Ther Med [Internet]. 2021 Apr 14 [cited 2022 Mar 25];21(4):362. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33732335

15. Etemadifar M, Nouri H, Salari M, Sedaghat N. Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. Hum Vaccin Immunother [Internet]. 2022 Mar 3 [cited 2022 Mar 25];1–4. Available from: https://pubmed.ncbi.nlm.nih.gov/35239452/

16. Ahmad SA, Salih BK, Hama Hussein KF, Mikael TM, Kakamad FH, Salih AM. Aseptic meningoencephalitis after COVID-19 vaccination: A case report. Ann Med Surg [Internet]. 2021 Nov 1 [cited 2022 Mar 25];71:103028. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34777795

17. Kammeyer R, Piquet AL. Multiple co-existing antibodies in autoimmune encephalitis: A case and review of the literature. J Neuroimmunol. 2019 Dec 15;337.

18. Bohm PE, Chen JJ, Bhatti TM, Eggenberger ER. Neuro-Ophthalmic Features of Autoimmune Encephalitides. J Neuroophthalmol. 2020 Sep 1;40(3):385–97.

19. Henry C, Husson H, De Broucker T. Encéphalite limbique auto-immune avec anticorps antirécepteur NMDA associée un tératome de l'ovaire : une forme curable d'encephalite limbique paraneoplasique. Rev Neurol (Paris). 2009 Jan;165(1):70–5.

20. Ji S, Liu C, Bi Z, Gao H, Sun J, Bu B. Overlapping syndrome mimicking infectious meningoencephalitis in a patient with MOG and GFAP IgG. BMC Neurol [Internet]. 2021 Dec 1 [cited 2022 Mar 26];21(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34507542/

21. Azizi S, Vadlamuri DL, Cannizzaro LA. Treatment of Anti-GAD65 Autoimmune Encephalitis With Methylprednisolone. Ochsner J [Internet]. 2021 [cited 2022 Mar 26];21(3):312–5. Available from: https://pubmed.ncbi.nlm.nih.gov/34566516/

22. Pawar GR, Ratageri VH, Udaykumar R. Meningoencephalitis Associated with SARS-CoV-2 Infection. Indian J Pediatr [Internet]. 2021 May 1 [cited 2022 Mar 26];88(5):490. Available from: https://pubmed.ncbi.nlm.nih.gov/33625667/



Fig. 1; A: Axial view Brain CT without contrast demonstrates severe hydrocephalus before extra ventricular drainage. B: Sagittal view Brain MRI(11) with gadolinium did not any other pathologic without hydrocephalus. C: Axial Brain CT without contrast after extra ventricular drainage, that shows hydrocephalus was reduced.